ERR open access journal advertisement
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


EUROPEAN RESPIRATORY REVIEW, 2006;15: 85-89. doi:10.1183/09059180.00010006
© 2006 the European Respiratory Society

This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Donnell, D. E.
Right arrow Articles by Laveneziana, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by O'Donnell, D. E.
Right arrow Articles by Laveneziana, P.

Lung hyperinflation in COPD: the impact of pharmacotherapy

D. E. O'Donnell and P. Laveneziana

Division of Respiratory and Critical Care Medicine, Dept of Medicine, Queen's University, Kingston, ON, Canada.

CORRESPONDENCE: D. E. O'Donnell, 102 Stuart Street, Kingston, ON, Canada K7L 2V6. Fax: 1 6135491459. E-mail: odonnell{at}post.queensu.ca

Improvement in airway function in response to bronchodilator therapy is generally confirmed by simple spirometry. However, improvements in maximal expiratory flow rates have been shown to correlate poorly with important patient-centred outcomes, such as reduced exertional dyspnoea and improved exercise performance. Recent studies have suggested that attendant reductions in end-expiratory lung volume as a result of bronchodilator-induced improvements in lung emptying may be more closely associated with symptom relief and increased exercise capacity than traditional spirometric indices. To the extent that chronic lung hyperinflation and the superimposition of acute dynamic hyperinflation (in response to increased ventilation or expiratory flow limitation) result in excessive loading and weakening of the inspiratory muscles, then pharmacological lung volume reduction should have important mechanical and sensory benefits for the patient.

The present article will examine the mechanisms of lung deflation following short-term bronchodilator therapy. The physiological links between reduced hyperinflation, improved dyspnoea and exercise endurance will be examined, and the emerging evidence for the additive effects of combining various modern pharmacological therapies will be reviewed.

KEYWORDS: Bronchodilators, chronic obstructive pulmonary disease, dynamic hyperinflation, dyspnoea, exercise, respiratory mechanics







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the European Respiratory Society.